These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33839885)

  • 1. Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial.
    Chandrasekhar J; Sartori S; Mehran R; Aquino M; Vogel B; Asgar AW; Webb JG; Tchetche D; Dumonteil N; Colombo A; Windecker S; Claessen BE; Ten Berg JM; Hildick-Smith D; Wijngaard P; Lefèvre T; Deliargyris EN; Hengstenberg C; Anthopoulos P; Dangas GD
    Clin Res Cardiol; 2021 May; 110(5):649-657. PubMed ID: 33839885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 randomized trial.
    Asgar A; Chandrasekhar J; Mikhail G; Webb J; Lefèvre T; Tamburino C; Hildick-Smith D; Hambrecht R; Van Belle E; Widder J; Dumonteil N; Hink U; Jeger R; Linke A; Deliargyris E; Gao P; Mehran R; Hengstenberg C; Anthopoulos P; Dangas G;
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):144-153. PubMed ID: 27152677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial.
    Dangas GD; Lefèvre T; Kupatt C; Tchetche D; Schäfer U; Dumonteil N; Webb JG; Colombo A; Windecker S; Ten Berg JM; Hildick-Smith D; Mehran R; Boekstegers P; Linke A; Tron C; Van Belle E; Asgar AW; Fach A; Jeger R; Sardella G; Hink HU; Husser O; Grube E; Deliargyris EN; Lechthaler I; Bernstein D; Wijngaard P; Anthopoulos P; Hengstenberg C;
    J Am Coll Cardiol; 2015 Dec; 66(25):2860-2868. PubMed ID: 26477635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
    Linke A; Chandrasekhar J; Sartori S; Lefevre T; van Belle E; Schaefer U; Tchetche D; Sardella G; Webb J; Colombo A; Windecker S; Vogel B; Farhan S; Sorrentino S; Sharma M; Snyder C; Asgar A; Dumonteil N; Tamburino C; Hink U; Violini R; Stella P; Bernstein D; Deliargyris E; Hengstenberg C; Baber U; Mehran R; Anthopoulos P; Dangas G;
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):1016-1026. PubMed ID: 28498562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial.
    Zilberszac R; Chandiramani R; Hengstenberg C; Sartori S; Cao D; Chandrasekhar J; Schafer U; Tchetche D; Violini R; Jeger R; Van Belle E; Boekstegers P; Hambrecht R; Tron C; Dumenteil N; Linke A; Ten Berg JM; Deliargyris EN; Anthopoulos P; Mehran R; Dangas G
    Catheter Cardiovasc Interv; 2020 Sep; 96(3):E377-E386. PubMed ID: 31808295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
    Hengstenberg C; Chandrasekhar J; Sartori S; Lefevre T; Mikhail G; Meneveau N; Tron C; Jeger R; Kupatt C; Vogel B; Farhan S; Sorrentino S; Sharma M; Snyder C; Husser O; Boekstegers P; Hambrecht R; Widder J; Hildick-Smith D; De Carlo M; Wijngaard P; Deliargyris E; Bernstein D; Baber U; Mehran R; Anthopoulos P; Dangas G;
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):1027-1037. PubMed ID: 28493641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of coronary artery disease on clinical outcomes after TAVR: Insights from the BRAVO-3 randomized trial.
    Feldman D; Cao D; Sartori S; Zhang Z; Hengstenberg C; Tron C; Anthopoulos P; Widder JD; Meneveau N; Stella PR; Ferrari M; Jeger R; Violini R; Dumonteil N; Chen S; Yan R; Nicolas J; Razuk V; Spirito A; Vogel B; Mehran R; Dangas G
    Catheter Cardiovasc Interv; 2023 May; 101(6):1134-1143. PubMed ID: 37036268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bivalirudin during percutaneous coronary intervention in high-bleeding-risk elderly patients with chronic total occlusion: A prospective randomized controlled trial.
    Wang Y; Zhao HW; Wang CF; Fan CY; Zhang XJ; Zhu Y; Luo DF; Yu GN; Hou AJ; Luan B
    Catheter Cardiovasc Interv; 2019 Feb; 93(S1):825-831. PubMed ID: 30724035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral Embolism During Transcatheter Aortic Valve Replacement: The BRAVO-3 MRI Study.
    Van Belle E; Hengstenberg C; Lefevre T; Kupatt C; Debry N; Husser O; Pontana F; Kuchcinski G; Deliargyris EN; Mehran R; Bernstein D; Anthopoulos P; Dangas GD;
    J Am Coll Cardiol; 2016 Aug; 68(6):589-599. PubMed ID: 27208464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
    Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P;
    Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention: An Analysis From the National Cardiovascular Data Registry.
    Washam JB; Kaltenbach LA; Wojdyla DM; Patel MR; Klein AJ; Abbott JD; Rao SV
    Circ Cardiovasc Interv; 2018 Feb; 11(2):e005628. PubMed ID: 29432119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute Kidney Injury After Transcatheter Aortic Valve Replacement.
    Aalaei-Andabili SH; Pourafshar N; Bavry AA; Klodell CT; Anderson RD; Karimi A; Petersen JW; Beaver TM
    J Card Surg; 2016 Jul; 31(7):416-22. PubMed ID: 27212701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial.
    Camaj A; Claessen BE; Mehran R; Yudi MB; Power D; Baber U; Hengstenberg C; Lefevre T; Van Belle E; Giustino G; Guedeney P; Sorrentino S; Kupatt C; Webb JG; Hildick-Smith D; Hink HU; Deliargyris EN; Anthopoulos P; Sharma SK; Kini A; Sartori S; Chandrasekhar J; Dangas GD
    Catheter Cardiovasc Interv; 2020 Dec; 96(7):E688-E694. PubMed ID: 31943717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
    Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
    Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemorrhagic and ischemic outcomes after bivalirudin versus unfractionated heparin during carotid artery stenting: a propensity score analysis from the NCDR.
    Wayangankar SA; Abu-Fadel MS; Aronow HD; Kennedy KF; Gupta R; Yeh RW; Gray WA; Rosenfield K; Hennebry TA
    Circ Cardiovasc Interv; 2013 Apr; 6(2):131-8. PubMed ID: 23532554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and Predictors of Acute Kidney Injury Following Transcatheter Aortic Valve Replacement: Role of Changing Definitions of Renal Function and Injury.
    Rodriguez R; Hasoon M; Eng M; Michalek J; Liu Q; Hernandez B; Bansal S; Bailey SR; Prasad A
    J Invasive Cardiol; 2020 Apr; 32(4):138-141. PubMed ID: 31941833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of post-primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: A comprehensive pairwise and network meta-analysis of randomized controlled trials.
    Shah R; Matin K; Rogers KC; Rao SV
    Catheter Cardiovasc Interv; 2017 Aug; 90(2):196-204. PubMed ID: 27862911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study.
    Garcia-Garcia HM; Adamo M; Soud M; Yacob O; Picchi A; Sardella G; Frigoli E; Limbruno U; Rigattieri S; Diletti R; Boccuzzi G; Zimarino M; Contarini M; Russo F; Calabrò P; Andò G; Varbella F; Garducci S; Palmieri C; Briguori C; Karagiannis A; Valgimigli M
    Catheter Cardiovasc Interv; 2020 Nov; 96(6):1156-1171. PubMed ID: 31883294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute kidney injury after aortic valve replacement: incidence, risk factors and outcomes.
    Najjar M; Salna M; George I
    Expert Rev Cardiovasc Ther; 2015 Mar; 13(3):301-16. PubMed ID: 25592763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO-3 randomized trial.
    Razuk V; Camaj A; Cao D; Nicolas J; Hengstenberg C; Sartori S; Zhang Z; Power D; Beerkens F; Chiarito M; Meneveau N; Tron C; Dumonteil N; Widder JD; Ferrari M; Violini R; Stella PR; Jeger R; Anthopoulos P; Mehran R; Dangas GD
    Catheter Cardiovasc Interv; 2021 Nov; 98(6):E870-E880. PubMed ID: 33909348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.